State and territorial health departments have the ability to order COVID-19 therapeutic products seven days a week through the Health Partner Ordering Portal (HPOP) in a process known as “threshold and replenishment.” In this process, the federal government replenishes the available supply, replacing products ordered by sites in the jurisdiction the previous week. This ensures that the total amount of product available to jurisdictions each week is consistent, and this amount is known as a jurisdiction’s "threshold quantity."
Paxlovid and Lagevrio (molnupiravir) threshold amounts are determined on a pro rata population basis and replenishment occurs weekly.
Requests for additional products can be made by state and territorial health department officials at any time if the current supply is not sufficient to meet demand. The federal government tracks the amount of COVID-19 therapeutic products ordered through the HPOP portal each week, monitoring product availability for each state or territory.
COVID-19 Therapeutics Summary: For All Open Distribution Channels1
December 17, 2021 – April 30, 2023
| Therapeutic |
Courses Delivered |
Courses Administered2 |
| Paxlovid3 |
13,386,715 |
9,071,782 |
Lagevrio
|
3,023,021 |
1,317,979 |
Total:
View Data by Jurisdiction |
16,409,736 |
10,389,761 |
1States, territories, and federal entities, including HRSA
2Based on 92% of sites reporting as of April 30, 2023
3Includes Paxlovid and Renal Paxlovid
Data source: HHS-Tiberius
COVID-19 Therapeutics Summary: Previously Distributed Products
2020 – 2023
Therapeutics
(currently not in use) |
Courses Delivered |
Courses Administered |
| Evusheld (300mg doses) |
1,032,156 |
738,936 |
| Bebtelovimab |
739,889 |
624,633 |
| REGEN-COV |
2,878,138 |
2,078,587 |
| Bamlanivimab/Etesevimab |
642,125 |
610,753 |
| Sotrovimab |
706,692 |
302,209 |
COVID-19 Therapeutics Threshold Determinations
May 1, 2023 - May 31, 2023
| Monthly Threshold Determinations* |
Paxlovid
(Standard and Reduced Dose) |
Lagevrio
(molnupiravir) |
Total |
|
May 1 - May 31, 2023 |
2,450,200 |
194,911 |
2,645,111 |
*Starting May 2023, COVID-19 therapeutic threshold determinations are reported monthly.
Prior COVID-19 Therapeutic Product Distribution
Weekly Threshold Determinations
September 5, 2022 - April 30, 2023 |
Paxlovid
(Standard and Reduced Dose) |
Lagevrio
(molnupiravir) |
Total |
|
April 24 - April 30, 2023 |
612,165 |
48,604 |
660,769 |
|
April 17 - April 23, 2023 |
612,165 |
48,604 |
660,769 |
|
April 10 - April 16, 2023 |
612,165 |
48,604 |
660,769 |
|
April 3 - April 9, 2023 |
613,705 |
49,099 |
662,804 |
|
March 27 - April 2, 2023 |
612,165 |
48,604 |
660,769 |
|
March 20 - March 26, 2023 |
612,165 |
48,604 |
660,769 |
|
March 13 - March 19, 2023 |
612,165 |
48,604 |
660,769 |
|
March 6 - March 12, 2023 |
612,165 |
48,604 |
660,769 |
|
February 27 - March 5, 2023 |
613,705 |
49,099 |
662,804 |
|
February 20 - February 26, 2023 |
612,165 |
48,604 |
660,769 |
|
February 13 - February 19, 2023 |
612,165 |
48,604 |
660,769 |
|
February 6 - February 12, 2023 |
612,115 |
48,296 |
660,411 |
|
January 30 - February 5, 2023 |
613,655 |
48,791 |
662,446 |
